ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
13 sept. 2021 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021 Marseille, France, September 13, 2021 – ImCheck Therapeutics today announced that it will present...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
12 sept. 2021 19h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
29 juil. 2021 16h01 HE
|
MacroGenics, Inc.
Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) MeetingConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md.,...
Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress
30 juin 2021 08h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Burning Rock to Present Data on Its Early Detection ELSA-seq at ESMO Asia Virtual Congress 2020
20 oct. 2020 21h30 HE
|
Burning Rock Biotech Limited
GUANGZHOU, China, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that new data for its early detection ELSA-seq test...
Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
21 sept. 2020 12h45 HE
|
Provectus Biopharmaceuticals Inc.
Near-resolution of tumor burden, including extensive visceral hepatic diseaseExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT)...
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
21 sept. 2020 10h20 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark and BOTHELL, Wash., 21 September 2020 Data featured in late-breaking proffered paper oral presentation Biologics license application submission planned to support...
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
20 sept. 2020 09h10 HE
|
MacroGenics, Inc.
MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibitionRecommended Phase 2 dose established for MSS CRC, NSCLC expansion...
HalioDx contribution to precision medicine at ESMO 2020
18 sept. 2020 08h10 HE
|
HalioDx
HalioDx contribution to precision medicine at ESMO 2020 Marseille, France, September 18, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
18 sept. 2020 03h05 HE
|
Autolus Therapeutics plc
- AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Sept. 18, 2020 (GLOBE...